Clinical Trials ArenaOriginal article
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Data Readoutpositivepneumococcal vaccinePositive
AI Analysis
Summary
Vaxcyte's pneumococcal vaccine demonstrated non-inferiority against standard-of-care vaccines across nearly all serotypes in clinical trial data. The positive results drove Vaxcyte's stock higher.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Vaccine proved non-inferior to standard-of-care comparator on nearly all serotypes
Importance:7/10
Sentiment:
0.75
pneumococcal vaccinenon-inferiorityPhase 3stock positive
Read the original article
Published by Clinical Trials Arena on October 5, 2026 1:39 PM